-
Genetically engineered B lymphocytes were used for rapid detection and identification of pathogens, a methodology with potential use in diagnostics, biowarfare defense, and biomonitoring of food and water.
-
The following summary of selected abstracts from 3 meetings will be published in multiple parts. The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) met in Chicago September 14-17, 2003. The Infectious Disease Society of America (IDSA) met in San Diego October 9-12, 2003. The American Society of Tropical Medicine and Hygiene meets in Philadelphia December 3-7, 2003.
-
-
-
Atazanavir (Reyetaz®), an azapeptide class of protease inhibitors, was approved by the US FDA for use in HIV infection on June 20, 2003. Atazanavir (ATV) has a unique pharmacokinetic profile allowing for once-daily dosing, which is optimized when taken with food.
-
Azithromycin administration to patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection was associated with a reduction in number of exacerbations, improvement in airflow, and weight gain.
-
By determining whether 4 key risk factors are present, clinicians might be able to identify those patients with S aureus bacteremia who are at increased risk of serious, complicated infection.
-
Inactivated trivalent influenza vaccine did not reduce the incidence of acute otitis media among children 6-24 months of age.
-
In a multicenter study of occupational HIV exposures, 38% of source patients had genotype mutations associated with resistance to antiretroviral drugs. Recent antiretroviral treatment history was highly associated with resistance.
-
The results of genetic analysis of a strain of S aureus with high-level resistance to vancomycin suggest that this resistance was the consequence of genetic transfer from a VRE to an MRSA, each present in and on the unfortunate patient who served as the incubator.